Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 7, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Solid Tumor

Interventions

DRUG

Binimetinib

MEK inhibitor, 45mg oral tablet

DRUG

Encorafenib

BRAF inhibitor, 450mg oral capsule

Trial Locations (1)

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER